Eric W. Thomas

Array ( [id] => 6234931 [patent_doc_number] => 20100266635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-10-21 [patent_title] => 'HIVCON: AN HIV IMMUNOGEN AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 12/725651 [patent_app_country] => US [patent_app_date] => 2010-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 35688 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0266/20100266635.pdf [firstpage_image] =>[orig_patent_app_number] => 12725651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6070144 [patent_doc_number] => 20110044994 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-02-24 [patent_title] => 'HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 12/726245 [patent_app_country] => US [patent_app_date] => 2010-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 55220 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0044/20110044994.pdf [firstpage_image] =>[orig_patent_app_number] => 12726245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6379483 [patent_doc_number] => 20100316570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-16 [patent_title] => 'Protection of Virus from Immune Cell Uptake' [patent_app_type] => utility [patent_app_number] => 12/721287 [patent_app_country] => US [patent_app_date] => 2010-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 21770 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0316/20100316570.pdf [firstpage_image] =>[orig_patent_app_number] => 12721287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8113829 [patent_doc_number] => 08158130 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-04-17 [patent_title] => 'Method for the preparation of virus-like particles (VLPS) comprising heterologous multiple membrane spanning proteins' [patent_app_type] => utility [patent_app_number] => 12/720398 [patent_app_country] => US [patent_app_date] => 2010-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 33155 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/158/08158130.pdf [firstpage_image] =>[orig_patent_app_number] => 12720398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9354776 [patent_doc_number] => 08673307 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2014-03-18 [patent_title] => 'HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120' [patent_app_type] => utility [patent_app_number] => 12/719356 [patent_app_country] => US [patent_app_date] => 2010-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 41 [patent_no_of_words] => 12364 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12719356 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6500614 [patent_doc_number] => 20100215682 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-08-26 [patent_title] => 'DELETION OF THE BETA 20-21 LOOP IN HIV GP120 EXPOSES THE CD4 BINDING SITE FOR IMPROVED ANTIBODY BINDING AND ANTIBODY INDUCTION' [patent_app_type] => utility [patent_app_number] => 12/714085 [patent_app_country] => US [patent_app_date] => 2010-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 30163 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0215/20100215682.pdf [firstpage_image] =>[orig_patent_app_number] => 12714085 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6395529 [patent_doc_number] => 20100178302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-07-15 [patent_title] => 'CHRONIC PATHOGEN-EXPRESSING CELL LINES' [patent_app_type] => utility [patent_app_number] => 12/705032 [patent_app_country] => US [patent_app_date] => 2010-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 6023 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0178/20100178302.pdf [firstpage_image] =>[orig_patent_app_number] => 12705032 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10077343 [patent_doc_number] => 09115186 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-08-25 [patent_title] => 'Stabilized trimeric HIV-1 gp41 fusion polypeptides comprising the N-terminal heptad repeat (NHR) and foldon (FD) trimerization motif' [patent_app_type] => utility [patent_app_number] => 12/702209 [patent_app_country] => US [patent_app_date] => 2010-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 15 [patent_no_of_words] => 9366 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12702209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6228931 [patent_doc_number] => 20100183669 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-07-22 [patent_title] => 'Mannose immunogens for HIV-1' [patent_app_type] => utility [patent_app_number] => 12/656550 [patent_app_country] => US [patent_app_date] => 2010-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 6105 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0183/20100183669.pdf [firstpage_image] =>[orig_patent_app_number] => 12656550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7766878 [patent_doc_number] => 20120034597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-02-09 [patent_title] => 'METHODS OF MONITORING TREATMENT OF AVIREMIC HIV-INFECTED PATIENTS' [patent_app_type] => utility [patent_app_number] => 13/145307 [patent_app_country] => US [patent_app_date] => 2010-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 7107 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0034/20120034597.pdf [firstpage_image] =>[orig_patent_app_number] => 13145307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8435158 [patent_doc_number] => 08282926 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-10-09 [patent_title] => 'CCR5-specific antibodies with HIV neutralizing activity that recognize a linear dodecapeptide that mimics a conformational epitope in the second extracellular loop of CCR5' [patent_app_type] => utility [patent_app_number] => 12/647789 [patent_app_country] => US [patent_app_date] => 2009-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 26 [patent_no_of_words] => 19857 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12647789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6430326 [patent_doc_number] => 20100143305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-06-10 [patent_title] => 'TREATMENT OF HIV AND AIDS USING PROBIOTIC LACTOBACILLUS REUTERI' [patent_app_type] => utility [patent_app_number] => 12/633642 [patent_app_country] => US [patent_app_date] => 2009-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 9451 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0143/20100143305.pdf [firstpage_image] =>[orig_patent_app_number] => 12633642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7710325 [patent_doc_number] => 20120003266 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-05 [patent_title] => 'VIRUS LIKE PARTICLE COMPOSITIONS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 13/131287 [patent_app_country] => US [patent_app_date] => 2009-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 118 [patent_figures_cnt] => 118 [patent_no_of_words] => 22814 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13131287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6380750 [patent_doc_number] => 20100316698 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-16 [patent_title] => 'POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 12/620511 [patent_app_country] => US [patent_app_date] => 2009-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 114 [patent_figures_cnt] => 114 [patent_no_of_words] => 40806 [patent_no_of_claims] => 67 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0316/20100316698.pdf [firstpage_image] =>[orig_patent_app_number] => 12620511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9523602 [patent_doc_number] => 08747862 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-06-10 [patent_title] => 'Pathogenic west african human immunodeficiency virus type 2 (HIV-2) group F isolate' [patent_app_type] => utility [patent_app_number] => 13/129282 [patent_app_country] => US [patent_app_date] => 2009-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 9327 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13129282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6245586 [patent_doc_number] => 20100135989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-06-03 [patent_title] => 'ANTI-HIV AGENTS' [patent_app_type] => utility [patent_app_number] => 12/618098 [patent_app_country] => US [patent_app_date] => 2009-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 11864 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0135/20100135989.pdf [firstpage_image] =>[orig_patent_app_number] => 12618098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9749418 [patent_doc_number] => 08840890 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-09-23 [patent_title] => 'Rapid expression cloning of human monoclonal antibodies from memory B cells' [patent_app_type] => utility [patent_app_number] => 13/128837 [patent_app_country] => US [patent_app_date] => 2009-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 20 [patent_no_of_words] => 26852 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 801 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13128837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6395435 [patent_doc_number] => 20100178290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-07-15 [patent_title] => 'Methods for reducing viral load in HIV-1 infected patients' [patent_app_type] => utility [patent_app_number] => 12/590005 [patent_app_country] => US [patent_app_date] => 2009-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 55748 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0178/20100178290.pdf [firstpage_image] =>[orig_patent_app_number] => 12590005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6434187 [patent_doc_number] => 20100278853 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-04 [patent_title] => 'CONSTRAINED HIV V3 LOOP PEPTIDES AS NOVEL IMMUNOGENS AND RECEPTOR ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 12/579938 [patent_app_country] => US [patent_app_date] => 2009-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 43795 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0278/20100278853.pdf [firstpage_image] =>[orig_patent_app_number] => 12579938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8293981 [patent_doc_number] => 08221768 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-07-17 [patent_title] => 'Chimeric flavivirus immunogens comprising the Japanese encephalitis virus (JEV) prM signal sequence' [patent_app_type] => utility [patent_app_number] => 12/580080 [patent_app_country] => US [patent_app_date] => 2009-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 32194 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12580080 [rel_patent_id] =>[rel_patent_doc_number] =>)